What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?

Diabetes Research and Clinical Practice

Volumn 30, Issue SUPPL. 1, 1996, Pages

  Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

Advanced glycosylation; Advanced glycosylation endproduct (AGE); Atherosclerosis; Diabetes; Oxidation

Indexed keywords

AMINOGUANIDINE; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA;

ANIMALS; ARTERIOSCLEROSIS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; HYPERGLYCEMIA; LIPID METABOLISM; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0029942390     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(96)80048-9     Document Type: Article

References (42)

1. Diabetes and cardiovascular disease
2. Diabetes as an atherogenic factor
3. Diabetes Mellitus
4. Modifications of low-density lipoprotein that increases its atherogenicity
5. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type I diabetic patients with increased urinary albumin excretion
6. Lipoprotein disorders in diabetes mellitus
7. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from Type 1 (insulin-dependent) diabetic patients: Changes with metabolic control
8. Metabolism of low-density lipoprotein from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts
9. The low-density lipoprotein pathway and its relation to atherosclerosis
10. Initiation of Jipid peroxidation in biological systems
11. Chemistryand biochemistry of 4-hydroxynonenal malonaldehyde and related aldehydes
12. Highlights of current research involving superoxide and perhydroxyl radicals inaqueous solutions
13. Mechanisms and biological relevance of lipid peroxidation initiation
14. Evaluation of an isoluminol chemiluminescence assay for the detection of hydroperoxide in human blood plasma
15. Antioxidant defenses and lipid peroxidation in human blood plasma
16. The chemistry of the Maillard reaction under physiological conditions: a review
17. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging
18. Nonenzymatic glycosylation of low-density lipoprotein alters its biologic activity
19. Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater
20. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen; role in the in situ formation of immune complexes.
21. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein
22. Highaffinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules
23. Endothelial receptor-mediated binding of glucosemodified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
24. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy
25. Cachectin/TNF and IL-I induced by glucose-modified proteins: role in normal tissue remodeling
26. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
27. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide
28. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications
29. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo
30. Occurrence of 4-hydroxyalkenals in rat tissues determined as pentafluorobenzyl oxime derivatives by gas chromatography-mass spectrometry
31. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro
32. Advanced glycosylation endproducts in patients with diabetic nephropathy
33. diabetic-uremic serum advanced glycosylation end products are chemically reactive and resistant to dialysis therapy
34. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients
35. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity.J
36. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins
37. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification
38. Hemoglobin-AGE: a circulating marker of advanced glycosylation